RRN9 Antibody

What is RRP9 and what cellular functions does it perform?

RRP9, also known as Ribosomal RNA Processing 9, is a protein with a molecular mass of approximately 74 kDa that plays a critical mechanical role in ribosome biogenesis . It functions as a component of a nucleolar small nuclear ribonucleoprotein particle (snoRNP) that participates in the processing and modification of pre-ribosomal RNA (pre-rRNA) . RRP9 is part of the small subunit (SSU) processome, which represents the first precursor of the small eukaryotic ribosomal subunit .

During SSU processome assembly in the nucleolus, RRP9 works alongside other ribosome biogenesis factors, RNA chaperones, and ribosomal proteins to generate RNA folding, modifications, rearrangements, and cleavage. Additionally, it participates in targeted degradation of pre-ribosomal RNA by the RNA exosome . The protein is also known by multiple alternative names including RNU3IP2, U355K, U3 small nucleolar RNA-interacting protein 2, U3 small nucleolar ribonucleoprotein-associated 55 kDa protein, U3 snoRNP-associated 55 kDa protein, and U3-55K .

Which applications is the rabbit polyclonal RRP9 antibody suitable for?

The rabbit polyclonal RRP9 antibody (ab168845) has been validated for several research applications in molecular biology and cell biology research contexts. Specifically, this antibody has been confirmed to be suitable for:

• Western blot (WB) analysis - The antibody can be used at a recommended concentration of 0.4 μg/mL for detecting RRP9 in whole cell lysates from human cell lines such as 293T and HeLa .

• Immunoprecipitation (IP) - The antibody has been validated for use in IP applications to pull down RRP9 protein from human samples .

The antibody has been raised against a synthetic peptide within human RRP9 amino acids 150-250 . It has been cited in at least two scientific publications, indicating its use and acceptance in the research community. Additionally, the manufacturer covers this antibody with a product promise for the applications and species reactivity mentioned above .

How does the RRP9 antibody perform in different experimental systems?

The RRP9 antibody (ab168845) has demonstrated consistent performance in human experimental systems, specifically with human cell lines such as 293T and HeLa . When used in Western blot applications at the recommended concentration of 0.4 μg/mL, the antibody successfully detects RRP9 in whole cell lysates (50 μg loading) .

For experimental planning purposes, researchers should note that while the antibody has been primarily validated with human samples, its potential cross-reactivity with other species has not been fully characterized in the available data. The antibody was raised against a synthetic peptide within human RRP9 amino acids 150-250, making it optimally suited for human samples .

When designing experiments, researchers should consider:

• Sample preparation techniques - Standard cell lysis protocols appear suitable for RRP9 detection

• Loading requirements - 50 μg of whole cell lysate has been successfully used in published protocols

• Detection systems - Standard secondary antibody detection systems for rabbit primary antibodies should be compatible

For novel experimental systems or cell types not previously tested, preliminary validation experiments are recommended to confirm antibody performance.

How can RRP9 antibody be used to investigate nucleolar dynamics and ribosome biogenesis?

The RRP9 antibody provides a valuable tool for investigating the complex processes of nucleolar dynamics and ribosome biogenesis. Since RRP9 is a component of the small subunit (SSU) processome and participates in pre-ribosomal RNA processing, the antibody can be used to:

• Track the assembly and disassembly of the SSU processome during the cell cycle through immunofluorescence microscopy

• Investigate protein-protein interactions within the nucleolus through co-immunoprecipitation experiments with RRP9 antibody as the primary pull-down reagent

• Examine how RNA chaperones and ribosomal proteins associate with nascent pre-rRNA by combining RRP9 antibody pulldowns with RNA sequencing

• Monitor changes in nucleolar composition and structure during cellular stress responses, which often affect ribosome biogenesis

A representative experimental approach would involve immunoprecipitation with the RRP9 antibody followed by mass spectrometry to identify interaction partners. This could be complemented with RNA immunoprecipitation (RIP) to identify the RNA species that associate with RRP9, providing insights into its role in RNA processing and modification events.

Researchers investigating nucleolar stress responses could combine the RRP9 antibody with markers of nucleolar stress (such as p53 localization) to understand how ribosome biogenesis factors respond to cellular stressors.

What are the optimal experimental conditions for using RRP9 antibody in immunoprecipitation studies?

For immunoprecipitation studies using the RRP9 antibody (ab168845), researchers should consider the following optimized protocol based on successful applications:

• Lysis buffer composition:

  • 50 mM Tris-HCl (pH 7.5)

  • 150 mM NaCl

  • 1% NP-40 or Triton X-100

  • 0.5% sodium deoxycholate

  • Protease inhibitor cocktail

  • Phosphatase inhibitors (if phosphorylation studies are relevant)

• Cell preparation:

  • Use approximately 1-2 × 10⁷ cells per IP reaction

  • Wash cells with cold PBS prior to lysis

  • Lyse cells on ice for 30 minutes with gentle agitation

• Pre-clearing:

  • Incubate lysate with protein A/G beads for 1 hour at 4°C

  • Remove beads by centrifugation (13,000 rpm, 10 minutes, 4°C)

• Antibody incubation:

  • Use 2-5 μg of RRP9 antibody per reaction

  • Incubate overnight at 4°C with gentle rotation

• Bead capture:

  • Add protein A beads and incubate for 2-4 hours at 4°C

  • Wash beads 4-5 times with lysis buffer containing reduced detergent (0.1-0.2%)

• Elution:

  • Use SDS sample buffer and boil for 5 minutes

  • Alternatively, for native elution, use appropriate peptide competition

For co-immunoprecipitation studies targeting RRP9's interaction partners in the SSU processome, gentler lysis conditions may be preferred to maintain protein-protein interactions. Additionally, RNase inhibitors should be included when investigating RRP9's association with RNA components.

How can researchers differentiate between RRP9 and other nucleolar proteins with similar functions?

Differentiating between RRP9 and other nucleolar proteins with similar functions requires a multi-faceted approach:

• Antibody specificity validation:

  • Western blot with recombinant proteins to confirm specificity

  • Knockdown/knockout validation using siRNA or CRISPR-Cas9 systems

  • Peptide competition assays to confirm epitope specificity

• Subcellular fractionation and co-localization:

  • Nuclear vs. nucleolar fractionation to assess relative enrichment

  • Co-immunofluorescence with known nucleolar markers such as fibrillarin (for dense fibrillar component) or nucleolin (for granular component)

• Functional assays:

  • RNA immunoprecipitation followed by sequencing (RIP-seq) to identify distinct RNA targets

  • Proximity ligation assays to identify unique protein-protein interactions

  • CRISPR-Cas9 mediated knockout followed by RNA processing analysis

The following table highlights key differences between RRP9 and related nucleolar proteins:

By combining these approaches, researchers can effectively distinguish RRP9 from other nucleolar proteins with overlapping functions or similar molecular weights.

What controls should be included when using RRP9 antibody in Western blot applications?

When using the RRP9 antibody in Western blot applications, researchers should implement a comprehensive set of controls to ensure experimental validity:

• Positive controls:

  • Human 293T and HeLa whole cell lysates (50 μg) have been validated to express detectable levels of RRP9

  • Recombinant RRP9 protein (if available) at known concentrations

  • Samples with overexpressed tagged RRP9 (e.g., FLAG-RRP9 or GFP-RRP9)

• Negative controls:

  • RRP9 knockdown samples (siRNA or shRNA-treated cells)

  • RRP9 knockout samples (CRISPR-Cas9 edited cells)

  • Cell lines known to express very low or undetectable levels of RRP9

• Technical controls:

  • Secondary antibody only control (omit primary antibody)

  • Loading control antibody (e.g., GAPDH, β-actin, or α-tubulin)

  • Molecular weight marker to confirm the expected size (~74 kDa for RRP9)

• Validation controls:

  • Peptide competition assay using the immunizing peptide

  • Multiple antibodies targeting different epitopes of RRP9

  • Expected band pattern in different cellular fractions (e.g., enrichment in nuclear fraction)

When optimizing Western blot conditions, researchers should test different antibody concentrations around the recommended 0.4 μg/mL to determine the optimal signal-to-noise ratio for their specific experimental system. Additionally, for studies of RRP9 in non-human species, preliminary cross-reactivity tests should be performed, although the antibody specificity for species other than human has not been fully characterized in the provided data.

How can researchers determine RRP9 localization using immunofluorescence techniques?

Although the RRP9 antibody (ab168845) has not been explicitly validated for immunofluorescence (IF) applications in the provided data, researchers interested in studying RRP9 localization may adapt the following methodological approach:

• Sample preparation:

  • Culture cells on glass coverslips or chamber slides

  • Fix cells using 4% paraformaldehyde (10 minutes at room temperature)

  • Permeabilize with 0.2% Triton X-100 in PBS (5 minutes)

  • Block with 3-5% BSA or normal serum (1 hour at room temperature)

• Antibody incubation:

  • Test a range of primary antibody dilutions (1:50 to 1:500)

  • Incubate overnight at 4°C in a humidified chamber

  • Use appropriate fluorescent-conjugated secondary antibody (anti-rabbit)

• Co-staining markers:

  • Include nucleolar markers such as fibrillarin or nucleolin

  • Use DAPI for nuclear counterstaining

  • Consider co-staining with other SSU processome components

• Controls for specificity:

  • Peptide competition controls

  • siRNA knockdown of RRP9

  • Secondary antibody-only controls

• Imaging considerations:

  • Use confocal microscopy for optimal resolution of nucleolar structures

  • Capture Z-stacks to visualize the complete nucleolar volume

  • Consider super-resolution techniques for detailed localization studies

Since RRP9 is involved in pre-rRNA processing in the nucleolus, researchers should expect a predominantly nucleolar localization pattern with possible enrichment in specific subcompartments of the nucleolus. When interpreting results, compare the localization pattern with known nucleolar markers to determine the precise subnucleolar localization of RRP9.

For quantitative analyses, automated image analysis software can be used to measure colocalization coefficients between RRP9 and other nucleolar markers, providing insights into its functional associations within the nucleolus.

What challenges might researchers encounter when studying RRP9 expression in different cell types?

Researchers studying RRP9 expression across different cell types may encounter several challenges that require methodological considerations:

• Variable expression levels:

  • RRP9 expression may vary significantly between proliferating and quiescent cells due to differences in ribosome biogenesis requirements

  • Stem cells, cancer cells, and rapidly dividing cells may exhibit higher expression levels than differentiated or senescent cells

  • Quantitative Western blot with appropriate loading controls and standard curves may be necessary for accurate comparisons

• Cell type-specific interactions:

  • RRP9's interaction partners in the SSU processome may vary between cell types

  • Cell type-specific post-translational modifications may affect antibody recognition

  • Consider using co-immunoprecipitation followed by mass spectrometry to identify cell type-specific interaction networks

• Nuclear extraction efficiency:

  • Different cell types may require optimized nuclear extraction protocols

  • Tightly packed heterochromatin in certain cell types may sequester nuclear proteins

  • Consider using gradual extraction methods with increasing detergent strengths

• Antibody accessibility issues:

  • Fixation artifacts in certain cell types may mask antibody epitopes

  • Test multiple fixation protocols (PFA, methanol, acetone) for optimal epitope preservation

  • Epitope retrieval methods may be necessary for certain cell types

• Background and non-specific binding:

  • Certain cell types (e.g., hepatocytes) may exhibit higher background in immunoassays

  • Optimize blocking conditions (5% BSA, 5% normal serum, commercial blockers)

  • Consider alternative detection systems for problematic cell types

When studying primary cells or tissues, researchers should validate the RRP9 antibody specifically for each cell type or tissue of interest, as the standard validation has been performed primarily in established cell lines (293T and HeLa) . Additionally, for cell types with known nucleolar structural variations, specialized nucleolar isolation techniques may be required prior to protein analysis.

How can researchers address weak or absent signals when using RRP9 antibody in Western blot?

When encountering weak or absent signals in RRP9 Western blot experiments, researchers should consider the following troubleshooting approaches:

• Sample preparation:

  • Ensure complete cell lysis with appropriate buffers containing protease inhibitors

  • For nucleolar proteins like RRP9, consider specialized nuclear extraction protocols

  • Avoid repeated freeze-thaw cycles of protein samples

  • Verify protein concentration using reliable quantification methods

• Loading and transfer:

  • Increase protein loading amount (the validated protocol uses 50 μg of whole cell lysate)

  • Check transfer efficiency using reversible total protein stains (Ponceau S)

  • Consider using PVDF membranes instead of nitrocellulose for improved protein retention

  • Optimize transfer conditions for high molecular weight proteins

• Antibody conditions:

  • Increase primary antibody concentration (start with 2-5× the recommended 0.4 μg/mL)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Test different antibody diluents (5% BSA may reduce background compared to milk)

  • Use more sensitive detection systems (enhanced chemiluminescence substrate)

• Technical considerations:

  • Ensure samples are fully denatured (heat at 95°C for 5 minutes with reducing agent)

  • Use freshly prepared buffers and reagents

  • Include positive control samples (293T or HeLa cell lysates)

  • Consider using signal enhancement systems or amplification steps

If these approaches do not resolve the issue, researchers should investigate whether RRP9 expression is regulated in their experimental system, as certain conditions may downregulate RRP9 expression or lead to its degradation. Additionally, post-translational modifications or protein complexes may affect epitope accessibility in certain experimental contexts.

What are common pitfalls in RRP9 immunoprecipitation experiments and how can they be avoided?

Immunoprecipitation of RRP9 presents several potential challenges due to its nucleolar localization and involvement in protein complexes. Common pitfalls and their solutions include:

• Inefficient nuclear extraction:

  • Pitfall: Standard lysis buffers may not efficiently extract nuclear proteins

  • Solution: Use specialized nuclear extraction kits or protocols with higher salt concentrations (300-450 mM NaCl)

  • Approach: Consider stepwise extraction protocols that first remove cytoplasmic proteins before nuclear extraction

• Disruption of protein complexes:

  • Pitfall: Harsh lysis conditions may disrupt RRP9's native interactions

  • Solution: Use gentler lysis buffers (reduce detergent concentration to 0.1-0.3%)

  • Approach: Consider crosslinking before lysis to preserve transient interactions

• Non-specific binding:

  • Pitfall: High background due to non-specific binding to beads

  • Solution: Include thorough pre-clearing steps with beads alone

  • Approach: Use more stringent washing conditions after immunoprecipitation

• RNA-dependent interactions:

  • Pitfall: Some RRP9 interactions may be RNA-dependent and lost during RNase contamination

  • Solution: Include RNase inhibitors in lysis buffers

  • Approach: Perform parallel experiments with and without RNase treatment to identify RNA-dependent interactions

• Antibody cross-reactivity:

  • Pitfall: Antibody may recognize related proteins in the snoRNP family

  • Solution: Validate specificity using RRP9 knockdown controls

  • Approach: Consider using epitope-tagged RRP9 for cleaner results

A systematic approach to successful RRP9 immunoprecipitation should include optimization of each step in the protocol, with particular attention to nuclear extraction efficiency and preservation of native protein complexes. Additionally, researchers should consider whether their experimental questions require native conditions or if denaturing conditions would be more appropriate for specific applications.

How can researchers validate the specificity of RRP9 antibody in their experimental systems?

Rigorous validation of RRP9 antibody specificity is essential for generating reliable and reproducible research data. Researchers should implement the following comprehensive validation strategy:

• Genetic approaches:

  • siRNA/shRNA knockdown: Demonstrate reduced signal intensity after RRP9 depletion

  • CRISPR-Cas9 knockout: Show complete absence of signal in knockout cells

  • Overexpression: Demonstrate increased signal intensity with RRP9 overexpression

• Biochemical approaches:

  • Peptide competition: Pre-incubate antibody with immunizing peptide before application

  • Multiple antibodies: Use independent antibodies targeting different RRP9 epitopes

  • Recombinant protein: Test antibody against purified RRP9 protein

• Mass spectrometry validation:

  • Perform immunoprecipitation followed by mass spectrometry

  • Confirm RRP9 as the predominant protein in the precipitate

  • Identify expected interaction partners (components of SSU processome)

• Cross-reactivity assessment:

  • Test antibody reactivity in species other than human

  • Evaluate potential cross-reactivity with related proteins (other snoRNP components)

  • Check for non-specific bands in Western blot across different cell types

• Application-specific controls:

  • For Western blot: Include molecular weight markers and verify expected ~74 kDa band

  • For IP: Include IgG control and non-target protein controls

  • For IF (if developed): Include peptide competition and subcellular fractionation validation

The following validation matrix can be used to systematically document antibody specificity across different applications:

By implementing these validation approaches, researchers can confidently assess the specificity of the RRP9 antibody in their particular experimental systems and applications.

How can RRP9 antibody be used to study stress-induced changes in ribosome biogenesis?

Cellular stress responses often involve alterations in ribosome biogenesis pathways, making RRP9 a potential marker for stress-induced nucleolar reorganization. Researchers can use the RRP9 antibody to investigate these dynamics through:

• Stress response time-course analysis:

  • Monitor RRP9 expression, localization, and post-translational modifications following exposure to various stressors (oxidative stress, nutrient deprivation, heat shock)

  • Combine with markers of nucleolar stress to correlate RRP9 changes with nucleolar reorganization

  • Quantify changes in RRP9 protein levels relative to other ribosome biogenesis factors

• Protein-protein interaction dynamics:

  • Use co-immunoprecipitation with RRP9 antibody to identify stress-induced changes in interaction partners

  • Implement proximity ligation assays to visualize dynamic interactions in situ

  • Compare RRP9 interactome under normal versus stress conditions

• RRP9 post-translational modifications:

  • Immunoprecipitate RRP9 followed by mass spectrometry to identify stress-induced modifications

  • Develop assays to correlate specific modifications with functional outcomes

  • Engineer mutants to disrupt specific modification sites and assess functional consequences

• RNA processing analysis:

  • Investigate how stress affects RRP9's association with pre-rRNA and U3 snoRNA

  • Perform RNA immunoprecipitation under normal versus stress conditions

  • Analyze pre-rRNA processing intermediates to identify stress-induced processing defects

By implementing these approaches, researchers can gain insights into how the ribosome biogenesis machinery responds to cellular stress, with RRP9 serving as a key marker for SSU processome dynamics. This research direction may reveal novel mechanisms of stress adaptation and potential therapeutic targets for conditions associated with dysregulated ribosome biogenesis.

What role might RRP9 play in cancer cell biology and how can the antibody facilitate this research?

The role of RRP9 in cancer biology remains an emerging area of research, with several potential avenues for investigation using the RRP9 antibody:

• Expression analysis in cancer tissues:

  • Compare RRP9 expression levels between normal and cancerous tissues

  • Correlate expression levels with clinical parameters (stage, grade, prognosis)

  • Develop tissue microarray analysis protocols using optimized immunohistochemistry conditions

• Cancer cell proliferation and ribosome biogenesis:

  • Investigate how RRP9 expression correlates with cancer cell proliferation rates

  • Determine whether RRP9 knockdown affects cancer cell growth and survival

  • Use the antibody to monitor RRP9 expression following treatment with ribosome biogenesis inhibitors

• RRP9 in cancer drug response:

  • Monitor changes in RRP9 expression or localization following chemotherapy

  • Investigate whether RRP9 status predicts response to ribosome biogenesis-targeting drugs

  • Explore combinations of cancer therapeutics with agents affecting nucleolar function

• Cancer-specific RRP9 complexes:

  • Compare RRP9 interaction partners between normal and cancer cells

  • Identify cancer-specific post-translational modifications of RRP9

  • Investigate cancer-specific RNA targets of RRP9-containing complexes

Since many cancer cells exhibit upregulated ribosome biogenesis to support their high protein synthesis demands, RRP9 and other components of the pre-rRNA processing machinery may represent both biomarkers and potential therapeutic targets. The RRP9 antibody provides a valuable tool for these investigations, enabling researchers to monitor expression levels, identify interaction partners, and characterize functional changes in RRP9 across different cancer types and treatment conditions.

How does RRP9 antibody compare to antibodies against other nucleolar proteins like NOR90?

When selecting antibodies for nucleolar research, understanding the comparative advantages and limitations of different options is essential:

• Target expression and localization:

  • RRP9 antibody targets a component of the SSU processome involved in pre-rRNA processing

  • NOR90 antibodies recognize components of the nucleolar organizer regions and are primarily used as diagnostic markers in clinical settings

  • RRP9 provides more specific information about the pre-rRNA processing machinery

  • NOR90 antibodies are more useful for studying the nucleolar organizing regions and rDNA transcription sites

• Clinical vs. basic research applications:

  • RRP9 antibody is primarily used in basic research of ribosome biogenesis

  • NOR90 antibodies have established clinical relevance in autoimmune conditions like systemic sclerosis

  • The prevalence of anti-NOR90 antibodies in systemic sclerosis patients is approximately 3.3%

  • RRP9 antibody has not been extensively characterized in clinical settings

• Specificity and cross-reactivity:

  • RRP9 antibody has been validated for human samples in Western blot and IP applications

  • NOR90 antibodies may cross-react with multiple nucleolar components

  • RRP9 provides more specific information about a single protein's function

  • NOR90 antibodies may be more useful as general nucleolar markers

The following comparison table highlights key differences between these antibodies:

When designing experiments requiring nucleolar markers, researchers should select the antibody that best aligns with their specific research questions and experimental approaches.